Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib

The use of selective inhibitors targeting Bcr-Abl kinase is now established as a standard protocol in the treatment of chronic myelogenous leukemia; however, the acquisition of drug resistance is a major obstacle limiting the treatment efficacy. To elucidate the molecular mechanism of drug resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, T-M, Ha, S-A, Kim, H K, Yoo, J, Kim, S, Yim, S-H, Jung, S-H, Kim, D-W, Chung, Y-J, Kim, J W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255246/
https://www.ncbi.nlm.nih.gov/pubmed/22829191
http://dx.doi.org/10.1038/bcj.2011.32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255246/
https://www.ncbi.nlm.nih.gov/pubmed/22829191
http://dx.doi.org/10.1038/bcj.2011.32

Ejemplares similares